Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.12.29.21268525: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Additionally, anti–SARS-CoV-2 antibody content was assessed in each donation, with a requirement for a SARS-CoV-2 seroneutralization titer ≥40 (≥80 after October 2020) and/or an immunoglobulin G (IgG) enzyme-linked immunosorbent assay (EUROIMMUN, Bussy-Saint-Martin, France) ratio >5.6 (≥8 after October 2020). anti–SARS-CoV-2suggested: NoneBussy-Saint-Martinsuggested: NoneCovariates considered in univariable analysis were gender, age (≥70 years versus below), comorbidities (diabetes, high blood pressure, and body mass index), type of hematological malignancies, previous B-cell depletion therapy such … SciScore for 10.1101/2021.12.29.21268525: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Additionally, anti–SARS-CoV-2 antibody content was assessed in each donation, with a requirement for a SARS-CoV-2 seroneutralization titer ≥40 (≥80 after October 2020) and/or an immunoglobulin G (IgG) enzyme-linked immunosorbent assay (EUROIMMUN, Bussy-Saint-Martin, France) ratio >5.6 (≥8 after October 2020). anti–SARS-CoV-2suggested: NoneBussy-Saint-Martinsuggested: NoneCovariates considered in univariable analysis were gender, age (≥70 years versus below), comorbidities (diabetes, high blood pressure, and body mass index), type of hematological malignancies, previous B-cell depletion therapy such as anti-CD20 or anti-CD19 monoclonal antibodies (mAbs), time between symptoms onset and CCP transfusion, and disease status (complete remission, partial remission/stable disease, and progressive disease). anti-CD20suggested: (BD Biosciences Cat# 643397, RRID:AB_1645743)anti-CD19suggested: NoneSoftware and Algorithms Sentences Resources All analyses were done using R software version 3.6.1 and SAS® Software version 9.4 (Cary, North Carolina, USA). SAS®suggested: (SASqPCR, RRID:SCR_003056)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, those results present several limitations and raise several questions. In our longitudinal cohort, the risk of death reaches 80% and 64% for myeloid neoplasm and plasma cell neoplasm, respectively, that is twofold higher than reported in previous studies.1 We must point out a higher COVID-19 severity with 34% of patients with myeloid and plasma-cell neoplasm requiring for mechanical ventilation whereas only 13% for B-cell neoplasm at the time of CCP. Similarly, previous studies reported a better outcome after early CCP transfusion in non-hospitalized patients.21 Of note, we observed a lower overall survival in patients transfused within the first ten days after symptoms onset in univariable analysis, an association that disappeared in the multivariable analysis. A similar observation was made in the Recovery trial (in the CCP arm as well as the control arm) and may reflect more severe disease in patients hospitalized early in the course of the disease.22 Furthermore, 62% of patients transfused earlier (within the first ten days) transfusion in our cohort presented with myeloid or plasma-cell neoplasm. In our retrospective nested analysis, data were collected prospectively from two data sources: one for patients exposed to CCP and another one for patients not exposed to CCP. Such comparison could not identify causal effect of treatment exposure with the level of proof provided by randomized clinical trials. We have tried to limit bias by using statistical methods to c...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
